Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic's pain and ICD devices:

This article was originally published in Clinica

Executive Summary

Medtronic can now sell both its next-generation neurostimulation implant for chronic pain relief and a new implantable cardioverter- defibrillator (ICD). The SynergyPlus+ "pain pacemaker" is designed to give patients more control over the delivery of stimulation that blocks pain signals from reaching the brain while performing a variety of daily activities. It has the greatest number of programme options - up to 26 - available of any non-rechargeable neurostimulation system on the market and provides a level of therapy customisation that may result in fewer physician follow-up visits, claims the firm. The EnTrust single- and dual-chamber ICDs employ Medtronic's ATP During Charging feature, which automatically uses pacing pulses to painlessly stop fast, dangerous heartbeats, while concurrently preparing to deliver a shock if needed, with no delay.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT055665

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel